About Immix Biopharma, Inc.
https://www.immixbio.comImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia.
CEO
Ilya Rachman MBA,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLEICHROEDER LP
Shares:850K
Value:$4.22M
VANGUARD GROUP INC
Shares:730.16K
Value:$3.62M
LYNWOOD CAPITAL MANAGEMENT INC.
Shares:405K
Value:$2.01M
Summary
Showing Top 3 of 35
About Immix Biopharma, Inc.
https://www.immixbio.comImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.66M ▲ | $-7.59M ▼ | 0% | $-0.24 ▼ | $-7.48M ▼ |
| Q2-2025 | $0 | $6.72M ▲ | $-6.62M ▼ | 0% | $-0.22 ▼ | $-6.64M ▼ |
| Q1-2025 | $0 | $4.68M ▼ | $-4.54M ▲ | 0% | $-0.15 ▲ | $-4.62M ▲ |
| Q4-2024 | $0 | $4.99M ▼ | $-4.81M ▲ | 0% | $-0.17 ▲ | $-4.95M ▲ |
| Q3-2024 | $0 | $7.39M | $-7.15M | 0% | $-0.24 | $-7.37M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $15.95M ▲ | $20.08M ▲ | $11.82M ▲ | $8.26M ▲ |
| Q2-2025 | $11.64M ▼ | $15.64M ▼ | $10.98M ▲ | $4.65M ▼ |
| Q1-2025 | $15.92M ▼ | $19.89M ▼ | $10.3M ▲ | $9.59M ▼ |
| Q4-2024 | $17.68M ▼ | $22.95M ▼ | $9.7M ▲ | $13.25M ▼ |
| Q3-2024 | $19.69M | $25.14M | $7.59M | $17.55M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.59M ▼ | $-5.91M ▼ | $-372.46K ▼ | $10.61M ▲ | $4.31M ▲ | $-6.28M ▼ |
| Q2-2025 | $-6.62M ▼ | $-5.31M ▼ | $-127.63K ▼ | $1.11M ▲ | $-4.28M ▼ | $-5.44M ▼ |
| Q1-2025 | $-4.54M ▲ | $-1.69M ▼ | $-67.71K ▲ | $0 | $-1.76M ▲ | $-1.75M ▲ |
| Q4-2024 | $-4.81M ▲ | $-1.48M ▲ | $-507.15K ▼ | $0 | $-2.01M ▲ | $-1.98M ▲ |
| Q3-2024 | $-7.15M | $-4.04M | $-271.54K | $0 | $-4.28M | $-4.31M |
CEO
Ilya Rachman MBA,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLEICHROEDER LP
Shares:850K
Value:$4.22M
VANGUARD GROUP INC
Shares:730.16K
Value:$3.62M
LYNWOOD CAPITAL MANAGEMENT INC.
Shares:405K
Value:$2.01M
Summary
Showing Top 3 of 35